These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Update of pemetrexed in thoracic oncology]. Author: Brechot JM, Morère JF. Journal: Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984. Abstract: Efficacy of pemetrexed has been demonstrated in malignant pleural mesothelioma. This is based on the result of a phase III trial comparing cisplatin and pemetrexed to cisplatin alone, with a significant improvement of median survival in the doublet arm (11.4 versus 8.8 months, p = 0.048). This combination represents a new standard of chemotherapy in this disease. In non small cell lung cancer, pemetrexed has been compared as second line chemotherapy to docetaxel : efficacy was comparable (median survival of 8.3 months with pemetrexed and 7.9 months with docetaxel) but significant less hematological toxicity was observed in the pemetrexed arm compared to the docetaxel arm, especially grade 3-4 neutropenia (respectively 5.3 and 40.2%) and febrile neutropenia (1.9 versus 12.7%). The place of pemetrexed in elderly patients is under evaluation.[Abstract] [Full Text] [Related] [New Search]